Phototherapy 660 nm for the prevention of radiodermatitis in breast cancer patients receiving radiation therapy: study protocol for a randomized controlled trial

Marina Moreira Costa, Sidney Benedito Silva, Ana Luiza Pereira Quinto, Priscilla Furtado Souza Pasquinelli, Vanessa de Queiroz dos Santos, Gabriela de Cássia Santos, Daniela Francescato Veiga, Marina Moreira Costa, Sidney Benedito Silva, Ana Luiza Pereira Quinto, Priscilla Furtado Souza Pasquinelli, Vanessa de Queiroz dos Santos, Gabriela de Cássia Santos, Daniela Francescato Veiga

Abstract

Background: Breast neoplasms are the second most common type of cancer worldwide, and radiation therapy is a key component of their treatment. Acute skin reactions are one of the most common side effects of radiation therapy, and prevention of this adverse event has been investigated in several studies. However, a clinically applicable, preventative treatment remains unavailable. It has been demonstrated that application of a low-power laser can promote tissue repair. Therefore, the aim of this trial is to evaluate the effectiveness of an indium gallium aluminum phosphorus (InGaAIP) laser operated at 660 nm in preventing radiodermatitis in women undergoing adjuvant radiotherapy for breast cancer.

Methods/design: This is a two-arm, randomized controlled trial. A total of 52 patients undergoing radiotherapy for breast cancer (stages I to III) will be enrolled. Patients will be randomly assigned to an intervention group to receive laser therapy (n = 26) or a control group to receive a placebo (n = 26). The laser or placebo will be applied five days a week, immediately before each radiotherapy session. Skin reactions will then be graded weekly by a nurse, a radiotherapist, and an oncologist (all of whom will be blinded) using the Common Toxicity Criteria (CTC) developed by the National Cancer Institute and the Acute Radiation Morbidity Scoring Criteria developed by the Radiation Therapy Oncology Group. Patients will also answer a modified visual analogue scale for pain (a self-evaluation questionnaire). Primary and secondary outcomes will be the prevention of radiodermatitis and pain secondary to radiodermatitis, respectively.

Discussion: The ideal tool for preventing radiodermatitis is an agent that mediates DNA repair or promotes cell proliferation. Application of a low-power laser has been shown to promote tissue repair by reducing inflammation and inducing collagen synthesis. Moreover, this treatment approach has not been associated with adverse events and is cost-effective. Thus, the results of this ongoing trial may establish whether use of a low-power laser represents an ideal treatment option for the prevention of radiodermatitis.

Trial registration: ClinicalTrials.gov identifier: NCT02003599. Registered on 2 December 2013.

Figures

Figure 1
Figure 1
Plastic guide with a grid of 35 points to guide the application of the laser or placebo.

References

    1. Aistars J. The validity of skin care protocols followed by women with breast cancer receiving external radiation. Clin J Oncol Nurs. 2006;10:487–492. doi: 10.1188/06.CJON.487-492.
    1. Pommier P, Gomez F, Sunyach MP, D’Hombres A, Carrie C, Montbarbon X. Phase III randomized trial of Calendula oficcinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. J Clin Oncol. 2004;22:1447–1453. doi: 10.1200/JCO.2004.07.063.
    1. Zhang Y, Zhang S, Shao X. Topical agent therapy for prevention and treatment of radiodermatitis: a meta-analysis. Support Care Cancer. 2013;21:1025–1031. doi: 10.1007/s00520-012-1622-5.
    1. Perez CA, Brady LW. Principles and Practice of Radiation Oncology. 5. Philadelphia: Lippincott-Raven Press; 2008.
    1. Radiation Therapy Oncology Group: Acute Radiation Morbidity Scoring Criteria. []
    1. Porock D, Kristjanson L, Nikoletti S, Cameron F, Pedler P. Predicting the severity of radiation skin reactions in women with breast cancer. Oncol Nurs Forum. 1998;25:1019–1029.
    1. Bolderston A, Lloyd NS, Wong RK, Holden L, Robb-Blenderman L, Supportive Care Guidelines Group of Cancer Care Ontario Program in Evidence-Based Care The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer. 2006;14:802–817. doi: 10.1007/s00520-006-0063-4.
    1. Salvo N, Barnes E, van Draanen J, Stacey E, Mitera G, Breen D, Giotis A, Czarnota G, Pang J, De Angelis C. Prophylaxis and management of acute radiation- induced skin reactions: a systematic review of the literature. Curr Oncol. 2010;17:94–112.
    1. Dirier A, Akmansu M, Bora H, Gurer M. The effect of vitamin E on acute skin reaction caused by radiotherapy. Clin Exp Dermatol. 2007;32:571–573. doi: 10.1111/j.1365-2230.2007.02452.x.
    1. Hawkins D, Abrahamse H. Effect of multiple exposures of low-level laser therapy on the cellular responses of wounded human fibroblasts. Photomed Laser Sur. 2006;24:705–714. doi: 10.1089/pho.2006.24.705.
    1. Rampini MP, Ferreira EMS, Ferreira CG, Antunes HS. Utilização da terapia com laser de baixa potência para prevenção de mucosite oral: revisão de literatura. Rev Bras Cancerologia. 2009;55:59–68.
    1. Arun Maiya G, Sagar MS, Fernandes D. Effect of low level helium-neon (He-Ne) laser therapy in the prevention & treatment of radiation induced mucositis in head & neck cancer patients. Indian J Med Res. 2006;124:339–402.
    1. Arora H, Pai KM, Maiya A, Vidyasagar MS, Rajeev A. Efficacy of He-Ne Laser in the prevention and treatment of radiotherapy-induced oral mucositis in oral cancer patients. Oral Surg Med Oral Pathol Radiol Endod. 2008;105:180–186. doi: 10.1016/j.tripleo.2007.07.043.
    1. Bensadoun RJ, Nair RG. Low-level laser therapy in the prevention and treatment of cancer therapy-induced mucositis: 2012 state of the art based on literature review and meta-analysis. Curr Opin Oncol. 2012;24:363–370. doi: 10.1097/CCO.0b013e328352eaa3.
    1. Bjordal JM, Bensadoun RJ, Tunèr J, Frigo L, Gierde K, Lopes-Martins RA. A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis. Support Care Cancer. 2011;19:1069–1077. doi: 10.1007/s00520-011-1202-0.
    1. Zimin AA, Samoilova KA, Zhevago NA. Proliferation of normal and tumor cells in presence of sérum of patients with breast carcinoma after phototherapy with visible and near infrared light. Cell Tissue Biol. 2010;52:785–792.
    1. Omar MT, Shaheen AA, Zafar H. A systematic review of the effect of low- level laser therapy in the management of breast cancer-related lymphedema. Support Care Cancer. 2012;20:2977–2984. doi: 10.1007/s00520-012-1546-0.
    1. Dirican A, Andacoglu O, Johnson R, McGuire K, Mager L, Soran A. The short-term effects of low-level laser therapy in the management of breast-cancer-related lymphedema. Support Care Cancer. 2011;19:685–690. doi: 10.1007/s00520-010-0888-8.
    1. Lau RW, Cheing GL. Managing postmastectomy lymphedema with low-level laser therapy. Photomed Laser Surg. 2009;27:763–769. doi: 10.1089/pho.2008.2330.
    1. Carati CJ, Anderson SN, Gannon BJ, Piller NB. Treatment of postmastectomy lymphedema with low-level laser therapy: a double blind, placebo-controlled trial. Cancer. 2003;98:1114–1122. doi: 10.1002/cncr.11641.
    1. DeLand MM, Weiss RA, McDaniel DH, Geronemus RG. Treatment of radiation-induced dermatitis with light-emitting diode (LED) photomodulation. Lasers Surg Med. 2007;39:164–168. doi: 10.1002/lsm.20455.
    1. Bensadoun RJ, Franquin JC, Ciais G, Darcour V, Schubert MM, Viot M, Dejou J, Tardieu C, Benezery K, Nguyen TD, Laudoyer Y, Dassonville O, Poissonnet G, Vallicioni J, Thyss A, Hamdi M, Chauvel P, Demard F. Low energy He/Ne laser in the prevention of radiation-induced mucositis: a multicenter phase III randomized study in patients with head and neck cancer. Support Care Cancer. 1999;7:244–252. doi: 10.1007/s005200050256.
    1. Ferraz MB, Quaresma MR, Aquino LR, Atra E, Tugwell P, Goldsmith CH. Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol. 1990;17:1022–1024.
    1. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. []
    1. The R Project for Statistical Computing. []
    1. Benomar S, Boutayeb S, Laiva I, Errihani H, Hassam B, El Gueddari BK. Treatment and prevention of acute radiation dermatitis. Cancer Radiother. 2010;14:213–216. doi: 10.1016/j.canrad.2010.02.001.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren